Doxorubicin combined with a linker that binds to circulating albumin. Tumors concentrate albumin, thus increasing the delivery of the linker molecule with the attached doxorubicin to tumor sites. Doxorbucin selectively released at tumor site due to its acidic environment. The gene discussed is ALB; the disease is neoplasm.